DK3254681T3 - N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt Download PDF

Info

Publication number: DK3254681T3
Authority: DK; Denmark
Prior art keywords: pyridin; difluorphenyl; cyclohepta; imidazo; piperidin
Prior art date: 2012-02-27

Application number

DK17180587.2T

Other languages

English (en)

Inventor

Daniel Richard Roberts

Richard Raymond Schartman

Chenkou Wei

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-27

Filing date

2013-02-25

Publication date

2019-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3254681(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-25 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2019-09-30 Application granted granted Critical

2019-09-30 Publication of DK3254681T3 publication Critical patent/DK3254681T3/da

Links

-1 2,3-DIFLUORPHENYL Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK17180587.2T 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt DK3254681T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261603598P	2012-02-27	2012-02-27
EP13708603.9A EP2820016B1 (en)	2012-02-27	2013-02-25	N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number	Publication Date
DK3254681T3 true DK3254681T3 (da)	2019-09-30

Family

ID=47844498

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17180587.2T DK3254681T3 (da)	2012-02-27	2013-02-25	N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt
DK13708603.9T DK2820016T3 (da)	2012-02-27	2013-02-25	N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13708603.9T DK2820016T3 (da)	2012-02-27	2013-02-25	N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt

Country Status (26)

Country	Link
US (1)	US8759372B2 (da)
EP (2)	EP3254681B1 (da)
JP (2)	JP6208154B2 (da)
KR (2)	KR102220969B1 (da)
CN (1)	CN104136437B (da)
AU (1)	AU2013226361B2 (da)
BR (1)	BR112014021032B1 (da)
CA (1)	CA2865585C (da)
CY (2)	CY1119448T1 (da)
DK (2)	DK3254681T3 (da)
EA (1)	EA025358B1 (da)
ES (2)	ES2746031T3 (da)
HK (1)	HK1248111B (da)
HR (2)	HRP20171620T1 (da)
HU (2)	HUE047050T2 (da)
IL (1)	IL234272B (da)
LT (2)	LT3254681T (da)
MX (1)	MX352171B (da)
NO (1)	NO2935439T3 (da)
PL (2)	PL2820016T3 (da)
PT (2)	PT2820016T (da)
RS (2)	RS56556B1 (da)
SG (1)	SG11201404834XA (da)
SI (2)	SI2820016T1 (da)
SM (1)	SMT201700489T1 (da)
WO (1)	WO2013130402A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2807187B1 (en)	2012-01-26	2017-07-26	Christopher J. Soares	Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
RS56556B1 (sr) *	2012-02-27	2018-02-28	Bristol Myers Squibb Co	N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so
EP2815749A1 (en)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
FI3265102T3 (fi)	2015-03-06	2025-10-31	Atea Pharmaceuticals Inc	Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
JP7123932B2 (ja) *	2016-09-02	2022-08-23	クリストファージェイ．ソアレス	神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
PT3512863T (pt)	2016-09-07	2022-03-09	Atea Pharmaceuticals Inc	Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
CN115477679A (zh) *	2017-02-01	2022-12-16	阿堤亚制药公司	用于治疗丙型肝炎病毒的核苷酸半硫酸盐
DK4088720T3 (da) *	2018-03-25	2025-09-29	Pfizer Ireland Pharmaceuticals Unlimited Company	Rimegepant til cgrp-relaterede lidelser
CN112351799A (zh)	2018-04-10	2021-02-09	阿堤亚制药公司	具有硬化的hcv感染患者的治疗
KR20210116560A (ko) *	2019-01-20	2021-09-27	바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.	편두통 돌발을 치료하기 위한 cgrp 길항제
US12521389B2 (en) *	2019-06-14	2026-01-13	The Regents Of The University Of California	Therapeutic approach to lung disease
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
WO2022164941A1 (en)	2021-01-26	2022-08-04	Atea Pharmaceuticals, Inc.	Advantageous morphic form of at-527 hemi-sulfate salt
JP2024509165A (ja)	2021-03-02	2024-02-29	シージーアールピーダイアグノスティクスゲーエムベーハー	片頭痛の治療及び／又は発生の低減
AU2022291927A1 (en)	2021-06-17	2024-01-04	Atea Pharmaceuticals, Inc.	Advantageous anti-hcv combination therapy
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
WO2023034466A1 (en) *	2021-09-02	2023-03-09	Pfizer Ireland Pharmaceuticals	Cgrp antagonists for treating psoriasis
CN115850266A (zh) *	2021-09-26	2023-03-28	奥锐特药业(天津)有限公司	瑞美吉泮新晶型及其制备方法
CN116554164B (zh) *	2022-01-27	2025-10-03	奥锐特药业(天津)有限公司	一种瑞美吉泮的制备方法
WO2023175632A1 (en) *	2022-03-17	2023-09-21	Msn Laboratories Private Limited, R&D Center	Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) *	2023-03-02	2024-09-06	Natco Pharma Limited	A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) *	2024-03-13	2025-09-18	CNS Biosciences, Inc.	Method of treating neuropathic pain using an anti-cgrp inhibitor
WO2026074002A1 (en)	2024-10-02	2026-04-09	Krka, D.D., Novo Mesto	Crystalline salts of rimegepant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA24500A1 (fr) *	1997-03-21	1998-10-01	Lg Life Sciences Ltd	Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en)	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
US7855294B2 (en)	2004-03-05	2010-12-21	Banyu Pharmaceutical Co., Ltd.	Cycloalkanopyridine derivative
EP1802637B1 (en)	2004-10-13	2008-10-15	Merck & Co., Inc.	Cgrp receptor antagonists
US7745427B2 (en)	2004-10-22	2010-06-29	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
AU2007238894A1 (en)	2006-04-10	2007-10-25	Merck Sharp & Dohme Corp.	Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
DE102006017827A1 (de) *	2006-04-13	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue kristalline Verbindungen
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en)	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en)	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
RS56556B1 (sr) *	2012-02-27	2018-02-28	Bristol Myers Squibb Co	N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so

2013
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en not_active Ceased
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-02-25 SM SM20170489T patent/SMT201700489T1/it unknown
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active Active
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active Active
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/en unknown
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown

Also Published As

Publication number	Publication date
KR102220969B1 (ko)	2021-02-25
EP3254681A1 (en)	2017-12-13
DK2820016T3 (da)	2017-11-13
ES2746031T3 (es)	2020-03-04
LT2820016T (lt)	2017-10-25
CY1119448T1 (el)	2018-03-07
CA2865585C (en)	2019-12-10
EP2820016B1 (en)	2017-08-02
RS59295B1 (sr)	2019-10-31
EA025358B1 (ru)	2016-12-30
HUE034936T2 (hu)	2018-03-28
RS56556B1 (sr)	2018-02-28
HUE047050T2 (hu)	2020-04-28
CA2865585A1 (en)	2013-09-06
SG11201404834XA (en)	2014-09-26
PT3254681T (pt)	2019-10-01
JP6208154B2 (ja)	2017-10-04
BR112014021032B1 (pt)	2022-09-27
KR102076118B1 (ko)	2020-02-11
IL234272B (en)	2018-10-31
PT2820016T (pt)	2017-10-18
PL3254681T3 (pl)	2019-12-31
CY1122121T1 (el)	2020-11-25
MX2014009544A (es)	2014-11-10
PL2820016T3 (pl)	2018-01-31
KR20140130140A (ko)	2014-11-07
HRP20191655T1 (hr)	2019-12-13
CN104136437A (zh)	2014-11-05
US8759372B2 (en)	2014-06-24
SI2820016T1 (sl)	2017-11-30
JP6476253B2 (ja)	2019-02-27
JP2017226693A (ja)	2017-12-28
US20130225636A1 (en)	2013-08-29
LT3254681T (lt)	2019-09-25
KR20200016993A (ko)	2020-02-17
WO2013130402A1 (en)	2013-09-06
EA201491585A1 (ru)	2015-01-30
JP2015511581A (ja)	2015-04-20
SMT201700489T1 (it)	2017-11-15
ES2642737T3 (es)	2017-11-17
SI3254681T1 (sl)	2019-10-30
NO2935439T3 (da)	2018-03-31
AU2013226361B2 (en)	2017-09-21
HRP20171620T1 (hr)	2017-12-01
EP3254681B1 (en)	2019-06-19
AU2013226361A1 (en)	2014-10-16
EP2820016A1 (en)	2015-01-07
BR112014021032A2 (da)	2017-06-20
MX352171B (es)	2017-11-13
CN104136437B (zh)	2016-05-11
HK1248111B (en)	2020-04-17

Publication	Publication Date	Title
DK2820016T3 (da)	2017-11-13	N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt
ZA201906379B (en)	2023-03-29	1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
IL257886B (en)	2021-10-31	History of imidazo[5,4-c]quinoline and imidazo[5,4-c][5,1]naphthyridine as lrrk2 inhibitors
IL227496B (en)	2019-02-28	Pyrazolo[4,3–b]pyridines are converted as drugs
IL240397A0 (en)	2015-09-24	Forms of methyl {6,4-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [[b-4,3-pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
PL2807165T3 (pl)	2019-09-30	Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
CO7000778A2 (es)	2014-07-21	Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
ZA201405070B (en)	2016-03-30	1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
ZA201306542B (en)	2014-05-28	7-azaindole derivatives
DK2970260T3 (da)	2019-05-27	Imidazo-[4,5-c]pyridin- og pyrrolo-[2,3-c]pyridinderivater som ssao-inhibitorer
IL234802B (en)	2018-10-31	Mutated pyridopyrimidine compounds as flt3 inhibitors
BR112013022948A2 (pt)	2016-12-06	derivados de pirido [2,3 - b] pirazina e seus usos terapêuticos
IL241808B (en)	2018-04-30	History of n-(2, 3-dihydro-1h-pyrrolo [3,2-b] pyridine-5-yl)-4-quinazolinamine and n-(2, 3-dihydro-1h-indole-5-yl} – 4-quinazolinamine as perk inhibitors
SI2697223T1 (sl)	2016-10-28	Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-A)indol-ocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
CO7020916A2 (es)	2014-08-11	Utilizacion en terapeutica de derivados de imidazopiridina
BR112013013282A2 (pt)	2016-09-06	compostos de oxazolo[5,4-b]piridin-5-ila